ADC Therapeutics SA (NYSE:ADCT)
$ 3.265 0.055 (1.71%) Market Cap: 315.55 Mil Enterprise Value: 134.52 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 45/100

Q4 2023 ADC Therapeutics SA Earnings Call Transcript

Mar 13, 2024 / 12:30PM GMT
Release Date Price: $3.9 (-12.36%)
Operator

Welcome to the ADC Therapeutics fourth quarter and full Year 2023 financial results conference call. My name is norm, and I'll be operator for today's call. (Operator Instructions) I will now turn the call over to Nicole Riley, Head of Communications. Nicole, you may begin.

Nicole Riley
ADC Therapeutics SA - Head of Communications

Thank you, operator. This morning, we issued a press release announcing our fourth-quarter and full-year 2023 financial results and business update. This release is available on the ADCT website at ir.adctherapeutics.com under the Press Releases' section.

On today's call, Ameet Mallik, Chief Executive Officer; Kristen Harrington-Smith, Chief Commercial Officer; Mohamed Zaki, Chief Medical Officer; Patrick van Berkeland, Chief Scientific Officer; and Pepe Carmona, Chief Financial Officer, will discuss recent business highlights and review our fourth-quarter and full-year 2023 financial results before opening the call for questions.

Before we begin, I would like to remind listeners that some of the statements made

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot